



Economic and Social Council

1 November 2010

Original: English

Commission on Narcotic Drugs

Reconvened fifty-third session

Vienna, 2 December 2010

Agenda item 5

Improving the collection, reporting and analysis of data to monitor the implementation of the Political Declaration and Plan of Action on International Cooperation towards an Integrated and Balanced Strategy to Counter the World Drug Problem

Annual report questionnaire:

Part Three. Extent and patterns of and trends in drug use**

Note by the Secretariat

Pursuant to Commission on Narcotic Drugs resolution 52/12, a meeting of the expert group on data collection was held in Vienna from 12 to 15 January 2010 to review the current data collection tools and collection, collation, analysis and reporting processes. Pursuant to Commission decision 53/2, the Secretariat produced a revised version of the draft annual report questionnaire; the expert group held a meeting in Vienna from 11 to 13 October 2010 to finalize the questionnaire so that the Commission could adopt it at its reconvened fifty-third session. The Secretariat hereby transmits part three of the questionnaire; parts one, two and four will be made available in separate documents (E/CN.7/2010/19, E/CN.7/2010/20 and E/CN.7/2010/22).

* Reissued for technical reasons on 30 January 2012.

** The present document was submitted after the date required by the 10-week rule as the meeting of the expert group on data collection was held from 11 to 13 October 2010.



Annual report questionnaire

Part Three. Extent and patterns of and trends in drug use

Report of the Government of _____

Reporting year _____

Completed on (date) _____

Please return the completed questionnaire to: arq@unodc.org

The completed annual report questionnaire is due on: [date].

For technical support, contact:

	Telephone	Fax	E-mail
UNODC Vienna	1 800 123 456	1 800 654 321	arqhelp@unodc.org
Regional offices:			
[list]			

Note

This is a printable version of the annual report questionnaire, which is in the form of an Excel spreadsheet and is designed to be completed electronically. In this printable version, definitions of key terms used in the questionnaire are provided in the footnotes, whenever relevant; in the electronic version, these definitions (and additional instructions) are repeated throughout the questionnaire through the “Comments” function in Excel. The Excel spreadsheet also uses drop-down lists for some questions, allowing respondents to simply select from a list the answer that is most appropriate for their country.

Instructions

The annual report questionnaire consists of the following four parts:

- Part One. Legislative and institutional framework
- Part Two. Comprehensive approach to drug demand and supply reduction
- Part Three. Extent and patterns of and trends in drug use
- Part Four. Extent and patterns of and trends in drug crop cultivation and drug manufacture and trafficking

This is part three of the annual report questionnaire.

Respondents are asked to complete all questions. Where no data are available, this should be indicated by inserting two dashes (--) or writing "not known" in the appropriate cell. All questions refer to the reporting year, unless otherwise indicated.

Respondents

All countries are invited to identify a single focal point for reporting data on drugs. In exceptional and duly justified cases, respondents may identify additional technical contacts who may contribute to completing the questionnaire, indicating, if possible, which responses they contributed to.

Metadata

Respondents may refer to multiple sources in completing the annual report questionnaire. These sources may include published reports and/or data sets not in the public domain, including routinely collected data from treatment, law enforcement or other agencies. All sources referred to during the completion of the questionnaire should be listed in the section on metadata, which can be found at the end of each section of the questionnaire. This information helps UNODC to understand the information provided.

About the questions

In recognition of the fact that not all countries have detailed data on all the topics covered in the questionnaire, part three of the annual report questionnaire contains questions designed primarily to elicit quantitative information. When such quantitative information is not available, information on trends and situations may be provided, together with the source of that information.

Quantitative data or estimates

The questions are designed to elicit quantitative data or estimates. The annual report questionnaire includes standardized response categories but, should the data available not conform to those categories, they can still be included. Simply indicate the categories used (e.g. age range, drug category) in the space provided. Quantitative data or estimates should be provided for the reporting year. The year in which data were collected should always be specified. When such quantitative data or estimates are not available, the most recent figures may be provided.

Several questions relate to classes or types of drugs. Whenever applicable, it is important that the information requested relate to individual drugs. Although care

has been taken to include all major drugs, the pre-coded lists might not fully match the needs of every country. Therefore, in each list the opportunity has been provided to add other classes or types of drugs. These open categories can also be used to insert alternative groups of drugs. For example: some questions list “heroin” and “other illicit opioids”; if the only information available is on opioids in general (no types are specified), “any opioids” should be listed under “other drugs”.

Technical notes

Some technical terms are explained below.

Technical terms

Incidence	The proportion of individuals in a specific population who are newly diagnosed as having a specific health condition (e.g. HIV) or problem in a given time period (e.g. one year). For example: 2 per cent of persons aged 34 years and older residing in London reported having used marijuana for the first time in 2000.
Prevalence	<p>The proportion of individuals in a specific population with a given condition (e.g. HIV) or engaging in a particular type of behaviour (e.g. injecting drug use) in a given period. For example: 10 per cent of persons aged 34 years and older residing in London reported having used marijuana in 2000.</p> <p>The term “lifetime prevalence of drug use” refers to the proportion of individuals who have used a drug at least once in their lifetime.</p> <p>The term “annual prevalence of drug use” refers to the proportion of individuals who used a drug at least once in the 12 months prior to the survey.</p> <p>The term “past 30-day prevalence of drug use” refers to the proportion of individuals who used a drug at least once in the 30 days prior to the survey.</p>
Reference population	The population to which an estimate applies (e.g. people aged 15-64 years, students aged 15-16 years, injecting drug users etc.).
Reporting year	The year _____ (to be indicated each year).

Classes and types of drugs under international control (narcotic drugs and psychotropic substances)

Listed below are the classes and types of drugs included in the annual report questionnaire. In some cases, examples of particular drug types are provided, but the lists of these examples are not exhaustive.

Class of drug	Type of drug
Any illicit drug	All illicit drugs and substances under international control, including pharmaceutical opioids, stimulants, tranquillizers and sedatives, that are misused or used for non-therapeutic purposes. Alcohol and tobacco are not included.
Cannabis	Marijuana (herb) Hashish (resin)
Opioids	Heroin Opium Pharmaceutical opioids such as buprenorphine (e.g. Suboxone, Subutex), codeine, dextropropoxyphene, fentanyl, oxycodone (e.g. Oxycontin) hydrocodone (e.g. Vicodin), hydromorphone, methadone, morphine and pethidine Other illicit opioids (e.g. "homebake")
Cocaine	Powder (salt) "Crack" Other types of cocaine, such as coca paste, cocaine paste, cocaine base, <i>basuco</i> , <i>paco</i> and <i>merla</i>
Amphetamine-type stimulants	Amphetamine Methamphetamine Prescription stimulants such as amfepramone, fenetylline, methylphenidate (e.g. Ritalin), pemoline, phenmetrazine, phentermine and dextroamphetamine "Ecstasy"-type substances (e.g. MDA, MDE/MDEA, MDMA) ¹ Other illicit amphetamine-type stimulants (e.g. Captagon, methcathinone, 4-MTA, 2C-B, MDBD)
Sedatives and tranquillizers (for non-therapeutic/non-prescription use)	Benzodiazepines such as alprazolam (e.g. Xanax), clonazepam (e.g. Rivotril), diazepam (e.g. Valium), temazepam and flunitrazepam (e.g. Rohypnol) Barbiturates such as allobarbitol, barbitol, phenobarbital, pentobarbital, secbutabarbitol etc. <i>Gamma</i> -hydroxybutyric acid (GHB) Other sedative hypnotics: meprobamate, methaqualone (Mandrax) and zolpidem

¹ MDA=methylenedioxyamphetamine; MDEA=3,4-methylenedioxyethylamphetamine; MDMA=methylenedioxymethamphetamine.

Hallucinogens	Lysergic acid diethylamide (LSD) Other hallucinogens (e.g. phencyclidine (PCP), mushrooms with psychoactive properties, tryptamines)
Solvents and inhalants	
Other drugs such as those under national but not international control	Including <i>gamma</i> -butyrolactone (GBL), khat, piperazines (e.g. <i>N</i> -benzylpiperazine (BZP)), tramadol and ketamine

Respondents

Instructions

Provide details on the focal point charged with reporting drug data for your country. In the exceptional cases in which technical contacts have been identified, you may wish to list them in the table entitled “additional technical contacts”, indicating, if possible, which responses they have contributed to.

Focal point

Name	Position	Agency	Telephone	Fax	E-mail

Additional technical contacts (optional)

	Name	Position	Agency	Telephone	Fax	E-mail	Questions contributed to
<i>Example</i>	Mr. John Smith	Chief Statistician	Office of Drug Control	+44 221 6573	+44 221 6001	j.smith@odc.gov	6-9 and 10-13
Contributor 1							
Contributor 2							
Contributor 3							
Contributor 4							
Contributor 5							

Prevalence of drug use: general population

1. For questions 2-6, please specify the rationale used to support your assessment of the situation in the reporting year: (Check all that apply.)

- ☐ General population survey (year of survey _____)
☐ School population survey (year of survey _____)
☐ Drug seizures
☐ Expert consultation
☐ Indirect estimate
☐ Treatment register
☐ Hospital admissions
☐ Register of drug users _____
☐ Other (specify: _____)

Class and type of drugs	Question		
	2	3	4
	Has this drug been used in your country in the reporting year?	Rank these classes of drugs ^a in order of prevalence of use in the reporting year	Rank the drug types within each class of drugs in order of prevalence of use in the reporting year
	Yes No Not known		
Cannabis		<input type="text"/>	
Marijuana (herb)	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>		<input type="text"/>
Hashish (resin)	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>		<input type="text"/>
Other types of cannabis (specify) _____	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>		<input type="text"/>
Opioids		<input type="text"/>	
Opium	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>		<input type="text"/>
Heroin	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>		<input type="text"/>
Prescription opioids ^b			
(non-prescription/non-therapeutic use)	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>		<input type="text"/>
Other illicit opioids (specify) _____	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>		<input type="text"/>
Cocaine		<input type="text"/>	
Powder (salt)	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>		<input type="text"/>
"Crack"	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>		<input type="text"/>
Other types of cocaine (specify) ^c _____	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>		<input type="text"/>
Amphetamine-type stimulants		<input type="text"/>	
Amphetamine	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>		<input type="text"/>
Methamphetamine	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>		<input type="text"/>
"Ecstasy"-type substances	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>		<input type="text"/>
Prescription stimulants ^d			
(non-prescription/non-therapeutic use)	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>		<input type="text"/>
Other illicit amphetamine-type stimulants (specify) ^e _____	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>		<input type="text"/>

Tranquillizers and sedatives

(non-prescription/non-therapeutic use)

Benzodiazepines^fBarbiturates^gOther sedative hypnotics (specify)^h**Hallucinogens**

LSD

Other hallucinogens (specify)

Solvents and inhalants**Other drugs such as those under national but not international control (specify)ⁱ**^a For the purposes of this questionnaire, alcohol and tobacco are not included.^b Prescription opioids may include preparations containing buprenorphine, codeine, dextropropoxyphene, fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone and pethidine.^c Other types of cocaine include coca paste and cocaine paste, cocaine base, *basuco*, *paco*, *merla* etc. (based on the Multilateral Evaluation Mechanism of the Inter-American Drug Abuse Control Commission (CICAD)).^d Prescription stimulants may include preparations containing amfepramone, fenetylline, methylphenidate, pemoline, phenmetrazine and phentermine.^e Other illicit amphetamine-type stimulants may include preparations such as Captagon, methcathinone, 4-MTA, 2C-B, MDBD etc.^f Benzodiazepines may include preparations such as alprazolam, clonazepam, diazepam, temazepam and flunitrazepam (e.g. Rohypnol).^g Barbiturates may include preparations containing allobarbitol, barbital, phenobarbital, pentobarbital, secbutabarbitol etc.^h Other sedative hypnotics may include preparations containing meprobamate, methaqualone, zolpidem etc.ⁱ Other drugs such as those under national but not international control may include substances such as *gamma*-butyrolactone (GBL), khat, piperazines (e.g. *N*-benzylpiperazine), tramadol and ketamine.

Class and type of drugs	Question													
	5							6						
	How much has the prevalence of use of each class of drugs changed in the reporting year? ^{a, b}							How much has the prevalence of use of each type of drug changed in the reporting year? ^{a, b}						
	Large increase	Some increase	Stable	Some decrease	Large decrease	Not known		Large increase	Some increase	Stable	Some decrease	Large decrease	Not known	
Cannabis	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Marijuana (herb)								<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Hashish (resin)								<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Other types of cannabis (specify)								<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Opioids	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Opium								<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Heroin								<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	

Pharmaceutical opioids ^c (non-prescription/non-therapeutic use)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Other illicit opioids (specify)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Cocaine	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Powder (salt)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
"Crack"	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Other types of cocaine (specify) ^d	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Amphetamine-type stimulants	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Amphetamine	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Methamphetamine	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
"Ecstasy"-type substances	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Prescription stimulants ^e (non-prescription/non-therapeutic use)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Other illicit amphetamine-type stimulants (specify) ^f	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Tranquillizers and sedatives (non-prescription/non-therapeutic use)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Benzodiazepines ^g	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Barbiturates ^h	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Other sedative hypnotics (specify) ⁱ	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Hallucinogens	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
LSD	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Other hallucinogens (specify)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Solvents and inhalants	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Other drugs such as those under national but not international control (specify)^j	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

^a "Stable" refers to an estimated variation of under 5 per cent; "some increase" and "some decrease" refer to an estimated variation of between 5 and 10 per cent; "large increase" and "large decrease" refer to an estimated variation of more than 10 per cent.

^b The term "change in prevalence" refers to the change observed since the last reporting year. For instance, if the prevalence was estimated at 3.6 per cent in 2006 and changed to 3.9 per cent in 2007, the change over the reporting year would be of about 8 per cent. Such a change could be characterized as representing "some increase" in prevalence.

^c Pharmaceutical opioids may include preparations containing buprenorphine, codeine, dextropropoxyphene, fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone and pethidine.

^d Other types of cocaine include coca paste and cocaine paste, cocaine base, *basuco*, *paco*, *merla* etc. (based on the Multilateral Evaluation Mechanism of the Inter-American Drug Abuse Control Commission (CICAD)).

^e Prescription stimulants may include preparations containing amfepramone, fenetylline, methylphenidate, pemoline, phenmetrazine and phentermine.

^f Other illicit amphetamine-type stimulants may include preparations such as Captagon, methcathinone, 4-MTA, 2C-B, MDDP etc.

^g Benzodiazepines may include preparations such as alprazolam, clonazepam, diazepam, temazepam and flunitrazepam (e.g. Rohypnol).

^h Barbiturates may include preparations containing allobarbitol, barbitol, phenobarbitol, pentobarbitol, secbutabarbitol etc.

ⁱ Other sedative hypnotics may include preparations containing meprobamate, methaqualone, zolpidem etc.

^j Other drugs such as those under national but not international control may include substances such as *gamma*-butyrolactone (GBL), khat, piperazines (e.g. *N*-benzylpiperazine), tramadol and ketamine.

Metadata

What sources of information (published and unpublished) were referred to in answering these questions?

If your country does not provide quantitative data for questions 9-12, please provide a detailed rationale to support your answers to questions 2-4 above by describing the source of information used, the nature and number of key informants and any other indicators used in your assessment of the situation.

Prevalence/number of drug users: general population

7. Do you have data on the prevalence or number of drug users among the general population?
- ☐ Yes, for the whole population
☐ Yes, for part of the population
☐ No (go to question 13)
8. (a) In which year were the data collected? _____.
- (b) Which part of the country or the population is covered by the data? _____.
- (c) What is the size of the general population to which the estimates apply? _____.
- (d) What is the source of the data you are reporting?
- ☐ General population survey
☐ Indirect estimate
☐ Treatment register
☐ Register of drug users _____
☐ Other (specify: _____)

		Question								
		9			10		11			
		What is the lifetime prevalence among the general population?		What is the annual prevalence among the general population?		What is the past 30-day prevalence among the general population, if applicable?				
		Male (%)	Female (%)	Total (%)	Male (%)	Female (%)	Total (%)	Male (%)	Female (%)	Total (%)
Preferred age range: 15-64 years										
Age range used: _____										
Class and type of drugs										
Any illicit drug ^a										
Cannabis										
Marijuana (herb)										
Hashish (resin)										
Other types of cannabis (specify) _____										

Opium

Opium

Heroin

Pharmaceutical opioids^b

(non-prescription/

(non-prescription/
non-therapeutic use)

Other illicit opioids (specify)

[illegible]

Powder

Powder (salt)

“Crack”

Other types of cocaine

(specify)^c

[illegible]

Amphetamine

Amphetamine

Methamphetamine

“Ecstasy”-type substances

Prescription stimulants^d

(non-prescription/

non-therapeutic use)

Other illicit s

[illegible]

(non-prescription/

(non-prescription/

non-therapeutic use)

Benzodiazepines

Barbiturates⁸

Other (specify)^h[illegible]

LSD

LSD

Other hallucinogens (specify)

[illegible]

[illegible]

international control (specify) ⁱ

international control (specify) ⁱ

1

[illegible]

^a Excluding alcohol and tobacco, but including controlled substances that are misused or used for non-therapeutic purposes.

^b Pharmaceutical opioids may include preparations containing buprenorphine, codeine, dextropropoxyphene, fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone and pethidine.

^c Other types of cocaine include coca paste and cocaine paste, cocaine base, *basuco*, *paco*, *mer/a* etc. (based on the Multilateral Evaluation Mechanism of the Inter-American Drug Abuse Control Commission (CICAD)).

^d Prescription stimulants may include preparations containing amfepramone, fenetylline, methylphenidate, pemoline, phenmetrazine and phentermine.

^e Other illicit amphetamine-type stimulants may include preparations such as Captagon, methcathinone, 4-MTA, 2C-B, MDDP etc.

^f Benzodiazepines may include preparations such as alprazolam, clonazepam, diazepam, temazepam and flunitrazepam (e.g. Rohypnol).

^g Barbiturates may include preparations containing allobarbitol, barbital, phenobarbital, pentobarbital, secbutabarbitol etc.

^h Other sedative hypnotics may include preparations containing meprobamate, methaqualone, zolpidem etc.

ⁱ Other drugs such as those under national but not international control may include substances such as *gamma*-butyrolactone (GBL), khat, piperazines (e.g. *N*-benzylpiperazine), tramadol and ketamine.

Question 12

If your country maintains a register of drug users, what is the estimated number of drug users registered for each of the following drugs?

Class of drugs	Number of registered drug users
Any illicit drug ^a	
Cannabis	
Opioids	
Cocaine	
Amphetamine-type stimulants	
Tranquillizers and sedatives	
Hallucinogens	
Solvents and inhalants	
Other drugs such as those under national but not international control (specify)	

^a Excluding alcohol and tobacco, but including controlled substances that are misused or used for non-therapeutic purposes.

Metadata

What sources of information (published and unpublished) were referred to in answering these questions?

Prevalence/number of drug users: youth

13. Do you have data on the prevalence or number of drug users among youth?

- ☐ Yes, for the whole population
☐ Yes, for part of the population
☐ No (go to question 18)

14. (a) In which year were the data collected? _____.

(b) Which part of the country or sub-group of the population is covered by the data? _____.

(c) What is the size of the youth population to which the estimates apply? _____.

(d) What is the source of the data you are reporting?

- ☐ School survey
☐ General population survey
☐ Indirect estimate
☐ Treatment or other register of drug users
☐ Other (specify: _____)

		Question 15					Question 16					Question 17				
		What is the lifetime prevalence among youth?					What is the annual prevalence among youth?					What is the past 30-day prevalence among youth, if applicable?				
		Male (%)	Female (%)	Total (%)	Male (%)	Female (%)	Total (%)	Male (%)	Female (%)	Total (%)	Male (%)	Female (%)	Total (%)			
Class and type of drugs																
Any illicit drug^a																
Cannabis																
Marijuana (herb)																
Hashish (resin)																
Other types of cannabis (specify)																
Opioids																
Opium																
Heroin																
Pharmaceutical opioids ^b (non-prescription/non-therapeutic use)																

^a Excluding alcohol and tobacco, but including controlled substances that are misused or used for non-therapeutic purposes.

- ^b Pharmaceutical opioids may include preparations containing buprenorphine, codeine, dextropropoxyphene, fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone and pethidine.
- ^c Other types of cocaine include coca paste and cocaine paste, cocaine base, *basuco*, *paco*, *merla* etc. (based on the Multilateral Evaluation Mechanism of the Inter-American Drug Abuse Control Commission (CICAD)).
- ^d Prescription stimulants may include preparations containing amfepramone, fenetylline, methylphenidate, pemoline, phenmetrazine and phentermine.
- ^e Other illicit amphetamine-type stimulants may include preparations such as Captagon, methcathinone, 4-MTA, 2C-B, MDDP etc.
- ^f Benzodiazepines may include preparations such as alprazolam, clonazepam, diazepam, temazepam and flunitrazepam (e.g. Rohypnol).
- ^g Barbiturates may include preparations containing allobarbitol, barbitol, phenobarbital, pentobarbital, secbutabarbitol etc.
- ^h Other sedative hypnotics may include preparations containing meprobamate, methaqualone, zolpidem etc.
- ⁱ Other drugs such as those under national but not international control may include substances such as *gamma*-butyrolactone (GBL), khat, piperazines (e.g. *N*-benzylpiperazine), tramadol and ketamine.

Metadata

What sources of information (published and unpublished) were referred to in answering these questions?

Injecting drug use*

Class and type of drugs	Question								
	18			19					20
	Has there been drug use by injection in the reporting year?			What has been the trend with regard to injecting drug use in the reporting year? ^a					Has there been sharing of needles or syringes among injecting drug users in the reporting year? <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Not known
	Yes	No	Not known	Large increase	Some increase	Stable	Some decrease	Large decrease	Not known
Any illicit drug^c	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Opioids	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Opium	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Heroin	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Pharmaceutical opioids ^d (non-prescription/ non-therapeutic use)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Other illicit opioids (specify) _____	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Cocaine	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Powder (salt)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
“Crack”	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Other types of cocaine (specify) ^e _____	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Amphetamine-type stimulants	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Amphetamine	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Methamphetamine	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Prescription stimulants ^f (non-prescription/ non-therapeutic use)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Other illicit stimulants (specify) ^g _____	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Tranquillizers and sedatives (non-prescription/ non-therapeutic use)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Benzodiazepines ^h	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Barbiturates ⁱ	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Other (specify) ^j _____	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

* An “injecting drug user” is a person who injects drugs for non-medical purposes.

Other drugs such as those under national but not international control (specify)^k

<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

^a “Stable” refers to an estimated variation of under 5 per cent; “some increase” and “some decrease” refer to an estimated variation of between 5 and 10 per cent; “large increase” and “large decrease” refer to an estimated variation of more than 10 per cent.

^b Injecting drug paraphernalia used to prepare drugs for use include cookers, water cups, filters, spoons, swabs, ampoules and other containers used for drug preparation, storage and transport.

^c For the purposes of this questionnaire, alcohol and tobacco are not included.

^d Pharmaceutical opioids may include preparations containing buprenorphine, codeine, dextropropoxyphene, fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone and pethidine.

^e Other types of cocaine include coca paste and cocaine paste, cocaine base, *basuco*, *paco*, *merla* etc. (based on the Multilateral Evaluation Mechanism of the Inter-American Drug Abuse Control Commission (CICAD)).

^f Prescription stimulants may include preparations containing amfepramone, fenetylline, methylphenidate, pemoline, phenmetrazine and phentermine.

^g Other illicit amphetamine-type stimulants may include preparations such as Captagon, methcathinone, 4-MTA, 2C-B, MDBD etc.

^h Benzodiazepines may include preparations such as alprazolam, clonazepam, diazepam, temazepam and flunitrazepam (e.g. Rohypnol).

ⁱ Barbiturates may include preparations containing allobarbitol, barbitol, phenobarbital, pentobarbital, secbutabarbitol etc.

^j Other sedative hypnotics may include preparations containing meprobamate, methaqualone, zolpidem etc.

^k Other drugs such as those under national but not international control may include substances such as *gamma*-butyrolactone (GBL), khat, piperazines (e.g. *N*-benzylpiperazine), tramadol and ketamine.

Metadata

What sources of information (published and unpublished) were referred to in answering these questions?

If your country does not provide quantitative data for questions 25 and 26, please provide a detailed rationale to support your answers to questions 18-22 above by describing the source of information used, the nature and number of key informants and any other indicators used in your assessment of the situation.

Injecting drug users

23. Do you have data on the total number of injecting drug users in your country?

- ☐ Yes, for the whole country
☐ Yes, for part of country or sub-population
☐ No (go to question 28)

24. (a) In which year were the data collected? _____.

(b) Which part of the country or sub-group of the population is covered by the data? _____.

(c) What is the size of the population to which the estimates apply? _____.

(d) What is the source of the data you are reporting?

- ☐ Behavioural survey
☐ Treatment and other register of drug users
☐ Indirect estimates
☐ General population survey
☐ Other (specify: _____)

Class and type of drugs	Question		
	25	26	27
	What percentage of users of each drug injects that drug?	What is the estimated number of people who inject each drug?	What percentage of injecting drug users shared needles or syringes? ^a
			Preferred time frame: last time injected Time frame used:
Any illicit drug^b			
Illicit opioids			
Heroin			
Opium			
Pharmaceutical opioids ^c			
(non-prescription/non-therapeutic use)			
Other illicit opioids (specify)			

Cocaine			
Powder (salt)			
"Crack"			
Other types of cocaine (specify) ^d			

Amphetamine-type stimulants^e			
Amphetamine			
Methamphetamine			
Prescription stimulants ^f			
(non-prescription/non-therapeutic use)			
Other illicit stimulants (specify) ^g			

Tranquillizers and sedatives

(non-prescription/non-therapeutic use)

Benzodiazepines^hBarbituratesⁱOther (specify)^j**Other drugs such as those under national
but not international control (specify)^k**

^a The question should ideally refer to current injecting drug users (persons who have injected drugs in the 30 days prior to responding to the questionnaire) who shared needles, syringes or other injecting paraphernalia the last time they injected.

^b For the purposes of this questionnaire, alcohol and tobacco are not included.

^c Pharmaceutical opioids may include preparations containing buprenorphine, codeine, dextropropoxyphene, fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone and pethidine.

^d Other types of cocaine include coca paste and cocaine paste, cocaine base, *basuco*, *paco*, *merla* etc. (based on the Multilateral Evaluation Mechanism of the Inter-American Drug Abuse Control Commission (CICAD)).

^e Please specify whether the figures reported for use of illicit amphetamine-type stimulants include the non-prescribed/non-therapeutic use of prescription stimulants.

^f Prescription stimulants may include preparations containing amfepramone, fenetylline, methylphenidate, pemoline, phenmetrazine and phentermine.

^g Other illicit amphetamine-type stimulants may include preparations such as Captagon, methcathinone, 4-MTA, 2C-B, MDD etc.

^h Benzodiazepines may include preparations such as alprazolam, clonazepam, diazepam, temazepam and flunitrazepam (e.g. Rohypnol).

ⁱ Barbiturates may include preparations containing allobarbitol, barbital, phenobarbital, pentobarbital, secbutabarbitol etc.

^j Other sedative hypnotics may include preparations containing meprobamate, methaqualone, zolpidem etc.

^k Other drugs such as those under national but not international control may include substances such as *gamma*-butyrolactone (GBL), khat, piperazines (e.g. *N*-benzylpiperazine), tramadol and ketamine.

Metadata

What sources of information (published and unpublished) were referred to in answering these questions?

Severe/problem drug users^{*}

28. Do you have data regarding the number of severe/problem drug users in your country?
- ☐ Yes, for the whole country
- ☐ Yes, for part of country or sub-population
- ☐ No (go to question 34)
- 29.
- (a) In which year were the data collected? _____.
- (b) Which part of the country or sub-group of the population is covered by the data? _____.
- (c) What definition of "severe/problem drug user" applies to the data? _____.
- (d) What was the sample size to which the data apply? _____.
- (e) What is the source of the data you are reporting?
- ☐ Behavioural survey
- ☐ Treatment and other register of drug users
- ☐ General population survey
- ☐ Other (specify: _____)
- (f) Please select the estimation method used (i.e. indirect methods)? (Check all that apply.)
- ☐ Capture-recapture
- ☐ Multiplier benchmark treatment
- ☐ Multiplier benchmark police
- ☐ Multiplier benchmark mortality
- ☐ Other (specify: _____)
30. What is the estimated number of severe/problem drug users in your country? _____.
- (a) Opioids: _____
- (b) Cocaine: _____
- (c) Amphetamine-type stimulants: _____

* For the purposes of this questionnaire, "severe/problem drug users" are people who engage in the high-risk consumption of drugs, for example people who inject drugs, people who use drugs on a daily basis and/or people diagnosed as drug dependent, based on clinical criteria contained in the *International Classification of Diseases* (tenth revision) of the World Health Organization and the *Diagnostic and Statistical Manual of Mental Disorders* (fourth edition) of the American Psychiatric Association, or any similar criteria or definition that might be used.

High-risk groups

High-risk groups		Question	
31		32	33
	What is the estimated number of people in each high-risk group in your country?	What is the estimated annual prevalence within each group of any illicit drug use? Preferred time frame: 12 months Time frame used: _____	What is the annual prevalence of the three main drugs within each high-risk group?
Persons held in prisons ^a			1. 2. 3.
Persons in prostitution			1. 2. 3.
Homeless people			1. 2. 3.
Other high-risk groups (specify)			
			1. 2. 3.
			1. 2. 3.
^a "Persons held in prisons" are all persons held in public and privately financed institutions where persons are deprived of their liberty. These include penal, correctional, pretrial and psychiatric facilities that are part of the criminal justice system. The term does not apply to non-criminal prisoners held for administrative reasons, including persons held pending investigation into their immigration status.			

Metadata

What sources of information (published and unpublished) were referred to in answering these questions?

New developments in drug use

34. Have any new drugs or new patterns of drug use been observed in the reporting year?
<input type="checkbox"/> Yes <input type="checkbox"/> No (go to question 37)
35. Which new drugs or patterns of drug use have been observed? In which population groups have these new drugs or patterns of drug use emerged?
36. Use the space below to document any other developments in the prevalence and patterns of drug use in your country over the reporting year.

Metadata

What sources of information (published and unpublished) were referred to in answering these questions?

Drug-related morbidity

37. For question 38, please specify the rationale used in your assessment of the situation in the reporting year: (Check all that apply.)

- ☐ General population survey (year of survey _____)
☐ School population survey (year of survey _____)
☐ Drug seizures
☐ Expert consultation
☐ Indirect estimate
☐ Treatment register
☐ Hospital admissions
☐ Register of drug users _____
☐ Other (specify: _____)

Question 38

Has the prevalence of each of the infections listed below changed among injecting drug users in the reporting year?^a

Infection	Large increase	Some increase	Stable	Some decrease	Large decrease	Not known
Hepatitis B	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Hepatitis C	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
HIV	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Tuberculosis (active)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

^a "Stable" refers to an estimated variation of under 5 per cent; "some increase" and "some decrease" refer to an estimated variation of between 5 and 10 per cent; "large increase" and "large decrease" refer to an estimated variation of more than 10 per cent.

39. Do you have an estimate of the percentage of injecting drug users with any of the infections listed in question 38?

- ☐ Yes, for the whole population
☐ Yes, for a sub-group or part of the population
☐ No (go to question 44)

Infection	Question			
	40	41	42	43
	What is the estimated prevalence (%) of each infection among injecting drug users?	What is the estimated number of injecting drug users with each infection?	What is the estimated prevalence (%) of each infection among persons held in prisons? ^a	What is the estimated number of persons held in prisons, with each infection? ^a
Hepatitis B				
Hepatitis C				
HIV				
Tuberculosis				

^a The percentage should be reported for the entire prison population (not just for injecting drug users).

44. (a) In which year were the data referred to in question 40 collected? _____.
- (b) Which part of the country or sub-group of injecting drug users is covered by the estimate? _____.
- (c) What was the sample size of the population to which the estimate applies? _____.
- (d) What is the source of the data you are reporting?
- ☐ Behavioural survey
 - ☐ Treatment and other register of drug users
 - ☐ Indirect estimates
 - ☐ General population survey
 - ☐ Other (specify: _____)

Metadata

What sources of information (published and unpublished) were referred to in answering these questions?

Drug-related morbidity

45. Do you routinely collect data on the number of non-fatal drug-related consequences for health in your country?

- ☐ Yes, for the whole population
☐ Yes, for a sub-group or part of the population
☐ No (go to question 48)

46. On which consequences for health do you collect data? (Check all that apply.)

- ☐ Non-fatal drug overdoses²
☐ Drug-related hospital emergency room visits³

47. (a) In which year were the data referred to in question 46 collected? _____.

(b) Which part of the country or sub-group is covered by the estimate? _____.

Consequences for health	Question
	48
	What is the number of non-fatal drug-related episodes recorded during the reporting period?
Non-fatal drug overdoses	
Drug-related hospital emergency room visits	

Metadata

What sources of information (published and unpublished) were referred to in answering these questions?

² An "overdose" is the use of any drug in such quantities as to produce acute adverse physical or mental effects. Overdoses may have transient or lasting (non-fatal) effects or result in death (see the lexicon of alcohol and drug terms of the World Health Organization, available from www.who.int/substance_abuse/terminology/who_lexicon/en).

³ "Drug-related emergency room visits" are made in cases of overdoses, for detoxification, to address withdrawal symptoms, drug-related accidents and trauma, and to treat any related mental health conditions that a drug user may present (see information of the Drug Abuse Warning Network available from <https://dawninfo.samhsa.gov>).

Drug-related mortality*

Class and type of drugs	Question								
	49		50	51					
	Have there been reports of drug-related deaths in the reporting year?		Rank these drugs in order of their importance as a primary cause of drug-related deaths	What has been the trend over the reporting year with regard to drug-related deaths compared with the previous reporting year? ^a					
	Yes	No		Large increase	Some increase	Stable	Some decrease	Large decrease	Not known
Any illicit drug^p	<input type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Cannabis	<input type="checkbox"/>	<input type="checkbox"/>	<input type="text"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Opioids	<input type="checkbox"/>	<input type="checkbox"/>	<input type="text"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Heroin/morphine	<input type="checkbox"/>	<input type="checkbox"/>							
Opium	<input type="checkbox"/>	<input type="checkbox"/>							
Pharmaceutical opioids ^c	<input type="checkbox"/>	<input type="checkbox"/>							
Other opioids (specify)	<input type="checkbox"/>	<input type="checkbox"/>							
Cocaine	<input type="checkbox"/>	<input type="checkbox"/>	<input type="text"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Amphetamine-type stimulants	<input type="checkbox"/>	<input type="checkbox"/>	<input type="text"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Amphetamine/methamphetamine	<input type="checkbox"/>	<input type="checkbox"/>							
Prescription stimulants ^d	<input type="checkbox"/>	<input type="checkbox"/>							
"Ecstasy"-type substances	<input type="checkbox"/>	<input type="checkbox"/>							
Other stimulants (specify) ^e	<input type="checkbox"/>	<input type="checkbox"/>							
Tranquillizers and sedatives	<input type="checkbox"/>	<input type="checkbox"/>	<input type="text"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Benzodiazepines ^f	<input type="checkbox"/>	<input type="checkbox"/>							
Barbiturates ^g	<input type="checkbox"/>	<input type="checkbox"/>							
Other sedative hypnotics (specify) ^h	<input type="checkbox"/>	<input type="checkbox"/>							
Hallucinogens	<input type="checkbox"/>	<input type="checkbox"/>	<input type="text"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Solvents and inhalants	<input type="checkbox"/>	<input type="checkbox"/>	<input type="text"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

* "Drug-related mortality" refers to deaths directly or indirectly caused by the intake of illicit drugs and psychotropic substances. The use of illicit drugs and psychotropic substances can lead indirectly to deaths in cases of drug-induced violence and traffic accidents. The standards used for recording drug-related deaths or mortality may include ICD 10 or a country's own definitions and practices.

Other drugs such as those under national but not international control (specify)ⁱ

	<input type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	<input type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	<input type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

^a “Stable” refers to an estimated variation of under 5 per cent; “some increase” and “some decrease” refer to an estimated variation of between 5 and 10 per cent; “large increase” and “large decrease” refer to an estimated variation of more than 10 per cent.

^b For the purposes of this questionnaire, alcohol and tobacco are not included.

^c Pharmaceutical opioids may include preparations containing buprenorphine, codeine, dextropropoxyphene, fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone and pethidine.

^d Prescription stimulants may include preparations containing amfepramone, fenetylline, methylphenidate, pemoline, phenmetrazine and phentermine.

^e Other illicit amphetamine-type stimulants may include preparations such as Captagon, methcathinone, 4-MTA, 2C-B, MDBD etc.

^f Benzodiazepines may include preparations such as alprazolam, clonazepam, diazepam, temazepam and flunitrazepam (e.g. Rohypnol).

^g Barbiturates may include preparations containing allobarbitol, barbitol, phenobarbitol, pentobarbitol, secbutabarbitol etc.

^h Other sedative hypnotics may include preparations containing meprobamate, methaqualone, zolpidem etc.

ⁱ Other drugs such as those under national but not international control may include substances such as *gamma*-butyrolactone (GBL), khat, piperazines (e.g. *N*-benzylpiperazine), tramadol and ketamine.

Metadata

What sources of information (published and unpublished) were referred to in answering these questions?

If your country does not provide quantitative data for questions 54-56, please provide a detailed rationale to support your answers to questions 49 and 50 above by describing the source of information used, the nature and number of key informants and any other indicators used in your assessment of the situation.

Drug-related mortality

52. Do you have data regarding the number of drug-related deaths in your country?

- ☐ Yes, for the whole population
☐ Yes, for a sub-group or part of the population
☐ No (go to question 58)

53. (a) In which year were the data referred to in question 52 collected? _____.

(b) Which part of the country or sub-group of the population is covered by the data? _____.

(c) What is the size of the reference population to which the data apply? _____.

Class and type of drugs	Question		
	54	55	56
	What is the total number of drug-related deaths? ^a	What is the number of fatal drug overdoses? ^b	What is the number of drug-related HIV/AIDS deaths? ^c
Any illicit drug^d			
Cannabis			
Opioids			
Heroin/morphine			
Opium			
Pharmaceutical opioids ^e			
Other opioids (specify)			

Cocaine			
Amphetamine-type stimulants			
Amphetamine/methamphetamine			
Prescription stimulants ^f			
"Ecstasy"-type substances			
Other stimulants (specify) ^g			

Tranquillizers and sedatives			
Benzodiazepines ^h			
Barbiturates ⁱ			
Other sedative hypnotics (specify) ^j			

Hallucinogens			
Solvents and inhalants			
Other drugs such as those under national but not international control (specify)^k			

57. What proportion of these deaths were for polydrug use?			

^a "Drug-related mortality" refers to deaths directly or indirectly caused by the intake of illicit drugs and psychotropic substances. The use of illicit drugs and psychotropic substances can lead indirectly to deaths in cases of drug-induced violence and traffic accidents. The standards used for recording drug-related deaths or mortality may include the *International Classification of Diseases* (tenth revision) of the World Health Organization or a country's own definitions

and practices.

- ^b In a “fatal drug overdose”, an overdose or drug intoxication has been assessed as being the direct underlying cause of death. Such cases can be identified from general mortality registers based on the *International Classification of Diseases* (tenth revision) of the World Health Organization or a similar classification system, or from special mortality registers (if they include drug overdoses as a separate category), whichever system is applicable to a given country.
- ^c In a “drug-related HIV/AIDS death”, HIV/AIDS has been assessed as the direct underlying cause of death and injecting drugs has been identified as the mode of transmission of HIV.
- ^d For the purposes of this questionnaire, alcohol and tobacco are not included.
- ^e Pharmaceutical opioids may include preparations containing buprenorphine, codeine, dextropropoxyphene, fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone and pethidine.
- ^f Prescription stimulants may include preparations containing amfepramone, fenetylline, methylphenidate, pemoline, phenmetrazine and phentermine.
- ^g Other illicit amphetamine-type stimulants may include preparations such as Captagon, methcathinone, 4-MTA, 2C-B, MBDL etc.
- ^h Benzodiazepines may include preparations such as alprazolam, clonazepam, diazepam, temazepam and flunitrazepam (e.g. Rohypnol).
- ⁱ Barbiturates may include preparations containing allobarbitol, barbitol, phenobarbitol, pentobarbitol, secbutabarbitol etc.
- ^j Other sedative hypnotics may include preparations containing meprobamate, methaqualone, zolpidem etc.
- ^k Other drugs such as those under national but not international control may include substances such as *gamma*-butyrolactone (GBL), khat, piperazines (e.g. *N*-benzylpiperazine), tramadol and ketamine.

Criteria

What international or national criteria have been used to define drug-related mortality in the country?

Metadata

What sources of information (published and unpublished) were referred to in answering these questions?

Drug treatment*

Class of drugs	Question								
	58		59	60					
	Have people received treatment for problems with this class of drugs in the reporting year?		Rank these drugs in order of their importance as the primary reason for receiving treatment	Has there been any change in the number of people receiving treatment for each drug? ^a					
	Yes	No		Large increase	Some increase	Stable	Some decrease	Large decrease	Not known
Any illicit drug (total) ^b	<input type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Cannabis	<input type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Opioids	<input type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Cocaine	<input type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Amphetamine-type stimulants	<input type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Sedatives and tranquillizers	<input type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Hallucinogens	<input type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Solvents and inhalants	<input type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Other drugs such as those under national but not international control (specify) ^c									
_____	<input type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
_____	<input type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
_____	<input type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

^a “Stable” refers to an estimated variation of under 5 per cent; “some increase” and “some decrease” refer to an estimated variation of between 5 and 10 per cent; “large increase” and “large decrease” refer to an estimated variation of more than 10 per cent.

^b For the purposes of this questionnaire, alcohol and tobacco are not included.

^c Other drugs such as those under national but not international control may include substances such as *gamma*-butyrolactone (GBL), khat, piperazines (e.g. *N*-benzylpiperazine), tramadol and ketamine.

* “Drug treatment” is any structured intervention aimed specifically at addressing a person’s drug use, including stabilization or reduction of drug use, maintenance or abstinence regimes, behavioural therapy, medical or psychological interventions etc.

Metadata

What sources of information (published and unpublished) were referred to in answering these questions?

If your country does not provide quantitative data for questions 63 and 64, please provide a detailed rationale to support your answers to questions 58 and 59 above by describing the source of information used, the nature and number of key informants and any other indicators used in your assessment of the situation.

Drug treatment

61. Do you have any data regarding the number of people receiving drug treatment in your country?

- ☐ Yes, for the whole country
☐ Yes, for part of the country or some treatment facilities
☐ No (go to question 70)

62. (a) In which year were the data referred to in question 61 collected? _____.

(b) Which part of the country or what types of treatment facilities are covered by the data? _____.

Note: Questions 63-66 refer to the year specified in question 62 (a).

Class and type of drugs	Question			
	63	64	65	66
	What is the estimated number of people who received drug treatment? ^a	What percentage of people in drug treatment entered treatment for the first time ever?	What percentage of people in drug treatment are female?	What is the median age of people in drug treatment?
Any illicit drug (total)^b				
Primary drug^c				
Cannabis				
Opioids				
Heroin				
Opium				
Pharmaceutical opioids (non-prescription/non-therapeutic use) ^d				
Other illicit opioids (specify)				
Cocaine				
Other types of cocaine (specify) ^e				
Amphetamine-type stimulants				
Methamphetamine				
Amphetamine				
"Ecstasy"-type substances				
Prescription stimulants (non-prescription/non-therapeutic use) (specify) ^f				
Tranquillizers and sedatives				
Benzodiazepines ^g				
Barbiturates ^h				

Other sedative hypnotics (specify) ⁱ				
Hallucinogens				
LSD				
Other hallucinogens (specify)				
Solvents and inhalants				
Other drugs such as those under national but not international control (specify)^j				
What proportion of people were treated for polydrug use?				

^a In this question, the numbers should refer to individuals who have received treatment and who would normally be included in national reporting requirements.

^b For the purposes of this questionnaire, alcohol and tobacco are not included.

^c The "primary drug" is the main drug used by a person and for which he or she is seeking treatment.

^d Pharmaceutical opioids may include preparations containing buprenorphine, codeine, dextropropoxyphene, fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone and pethidine.

^e Other types of cocaine include coca paste and cocaine paste, cocaine base, *basuco*, *paco*, *merla* etc. (based on the Multilateral Evaluation Mechanism of the Inter-American Drug Abuse Control Commission (CICAD)).

^f Prescription stimulants may include preparations containing amfepramone, fenetylline, methylphenidate, pemoline, phenmetrazine and phentermine.

^g Benzodiazepines may include preparations such as alprazolam, clonazepam, diazepam, temazepam and flunitrazepam (e.g. Rohypnol).

^h Barbiturates may include preparations containing allobarbitol, barbitol, phenobarbital, pentobarbital, secbutabarbitol etc.

ⁱ Other sedative hypnotics may include preparations containing meprobamate, methaqualone, zolpidem etc.

^j Other drugs such as those under national but not international control may include substances such as *gamma*-butyrolactone (GBL), khat, piperazines (e.g. *N*-benzylpiperazine), tramadol and ketamine.

67. Does the total number of people in treatment reported above include people in treatment for the abuse of substances other than those under international control?

- ☐ Yes
☐ No

If the answer is yes, please specify the substances not under international control for which people are in treatment (_____).

68. What is the estimated proportion of drug users in need of treatment that are currently receiving treatment in your country?

- ☐ None or almost none
☐ A minority
☐ About half
☐ The majority
☐ All or almost all
☐ Not known

Definitions	Question
	69
	What definition of “people in drug treatment” applies to the responses provided to questions 62-66? ^a
All people receiving treatment in the reporting year	<input type="checkbox"/>
People starting treatment in the reporting year	<input type="checkbox"/>
People in treatment at census date	<input type="checkbox"/>
People discharged from treatment	<input type="checkbox"/>
Other (specify)	<input type="checkbox"/>

^a Check all that apply.

Metadata

What sources of information (published and unpublished) were referred to in answering these questions?

Collecting data and monitoring capacity

Registers, surveys and rapid situation assessments	Question 70				
	(a) Does your country collect the following data regarding drug use and treatment?				
	Yes	No			
Registers					
National data on drug treatment	<input type="checkbox"/>	<input type="checkbox"/>			
Register of all drug users	<input type="checkbox"/>	<input type="checkbox"/>			
Register of problem drug users	<input type="checkbox"/>	<input type="checkbox"/>			
Register on drug-related morbidity	<input type="checkbox"/>	<input type="checkbox"/>			
Register on drug-related mortality	<input type="checkbox"/>	<input type="checkbox"/>			
	(b) How often does your country carry out the following data collection activities regarding drug use and its health and social consequences?				
	Never	Once a year	Every two years	Every three to five years	Every six or more years
Surveys					
General population survey	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
School population survey	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Survey among drug users	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Survey among prisoners	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Indirect estimates	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Rapid situation assessments	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Other data collections (specify)					
	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Registers, surveys and rapid situation assessments	Question 71		
	How suitable do you think the following data sources are for estimating the drug situation in your country?		
	Not very	Somewhat	Very
Registers			
National data collection on drug treatment	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Register of problem drug users	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Register on drug-related morbidity	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Register on drug-related mortality	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Surveys			
General population survey	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
School population survey	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Survey among drug users	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Survey among prisoners	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Indirect estimates	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Rapid situation assessments	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Other data collections (specify)			
	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

72. What measures (if any) have been taken to improve data collection systems for monitoring drug use at the national level in your country? What are the main barriers to implementing improved data collection systems?

Metadata

What sources of information (published and unpublished) were referred to in answering these questions?

Additional comments

Use the space below to make notes and comments, to clarify any information contained in this questionnaire and to document any other issues that you wish to bring to the attention of UNODC. If your comment relates to a specific question in the questionnaire, please refer to the corresponding question number.